Preventive cardiologyEffect of Central Obesity, Low High-Density Lipoprotein Cholesterol and C-Reactive Protein Polymorphisms on C-Reactive Protein Levels During Treatment With Rosuvastatin (10 mg Daily)
Section snippets
Methods
The methods of this study have been described in detail previously.3, 4 In brief, Han Chinese patients aged ≥18 years with established coronary heart disease or coronary heart disease risk equivalent5 including some with familial hypercholesterolemia (FH) who were recruited for a pharmacogenetic study of the lipid response to rosuvastatin 10 mg/day were included for the analysis.3, 4 Patients with uncontrolled diabetes mellitus, hypertension or thyroid disease, and significant renal or hepatic
Results
The clinical characteristics of 281 subjects with good adherence to rosuvastatin and having hsCRP levels <10 mg/L, including 13 subjects with hsCRP levels less than the limit of detection, are listed in Table 1.
In univariate analysis, all covariates except smoking, previous CVD, LDL cholesterol level, and concomitant use of aspirin or nonsteroidal anti-inflammatory drugs were significantly associated with serum hsCRP levels (p <0.05). WC (p <0.001), body mass index (p <0.001), waist-to-hip
Discussion
Plasma hsCRP concentration is a heritable trait, and polymorphisms in CRP have a major influence on hsCRP levels in different populations.6, 8, 10, 11, 12 In this study, we have shown that the CRP variants rs1205 and rs2808630 and the common nonsynonymous SNP I27L in HNF1A were significantly associated with reduced hsCRP levels in patients receiving treatment with a potent statin that is known to reduce hsCRP levels. APOE has been related to CRP levels in various genetic studies8, 12 and in the
Acknowledgments
We thank Emily W.M. Poon for laboratory assistance and all the patients for their participation in this study.
References (21)
- et al.
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial
J Am Coll Cardiol
(2005) - et al.
Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study
Am J Hum Genet
(2008) - et al.
Association between C-reactive protein gene haplotypes and C-reactive protein levels in Taiwanese: interaction with obesity
Atherosclerosis
(2009) - et al.
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein
Am J Hum Genet
(2008) - et al.
Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykjavik Study
Atherosclerosis
(2006) - et al.
Relation of C-reactive protein to abdominal adiposity
Am J Cardiol
(2010) - et al.
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Lancet
(2009) - et al.
Eligibility for statin therapy by the JUPITER trial criteria and subsequent mortality
Am J Cardiol
(2010) - et al.
Determinants of CRP level in statin-treated patients
Curr Med Res Opin
(2008) - et al.
ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin
Clin Pharmacol Ther
(2010)
Cited by (14)
Serum High-Sensitive C-Reactive Protein Level and CRP Genetic Polymorphisms Are Associated with Abdominal Aortic Aneurysm
2017, Annals of Vascular SurgeryCitation Excerpt :Carlson et al.23 performed a systematic survey of the common nucleotide variations across the CRP gene in a large cohort study of cardiovascular risk and identified 7 SNPs as functionally important including rs1205 which was in the promoter region. In 2010, Hu et al.24 reported that rs1205 was independently associated with hsCRP levels before and after adjustment for other variables in the Chinese patients. In this study, we also confirmed that rs1205-CC was associated with higher serum hsCRP levels.
Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers
2022, Frontiers in Nutrition
This study was substantially supported by a grant from the Research Grants Council of the Hong Kong Special Administrative Region, Hong Kong, China (project CUHK 4472/06M).
Dr. Tomlinson has received research funding to perform clinical studies from AstraZeneca, Wilmington, Delaware; Bayer AG, Munich, Germany; Boehringer Ingelheim, Ingelheim, Germany; Daiichi Sankyo, Tokyo, Japan; Kowa Pharmaceuticals, Montgomery, Alabama; Merck & Company, Whitehouse Station, New Jersey; Merck Sharp & Dohme, Hoddesdon, United Kingdom; Novartis, Basel, Switzerland; Otsuka Pharmaceutical Company, Tokyo, Japan; Pfizer, Inc., New York, New York; Roche Diagnostics GmbH, Mannheim, Germany; Sanofi-Aventis, Paris, France; and Servier, Neuilly-sur-Seine, France. Dr. Tomlinson has acted as a consultant or speaker on occasions for AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb, New York, New York; GlaxoSmithKline, London, United Kingdom; Kowa Pharmaceuticals; Merck & Company; Merck Sharp & Dohme; Novartis; Pfizer, Inc.; Roche Diagnostics GmbH; Sanofi-Aventis; Schering-Plough, Kenilworth, New Jersey; and Servier.